Browse EX-10 agreements

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 16, 2026, is by and among Sadot Group Inc., a Nevada corporation with offices located at 295 E. Renfro Street, Suite 300, Burleson, Texas 76028 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

RECITALS

A.       The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the 1933 Act.

…

GUARANTY

** **

This GUARANTY, dated as of July 16, 2026 (this “Guaranty”), is made by each of the undersigned (each a “Guarantor”, and collectively, the “Guarantors”), in favor of [•], in its capacity as collateral agent (in such capacity, the “Collateral Agent” as hereinafter further defined) for the “Buyers” party to the Securities Purchase Agreement (each as defined below).

W I T N E S S E T H:

** **

WHEREAS, Sadot Group Inc., a Nevada corporation with offices located at 295 E. Renfro street, Suite 300, Burleson, Texas 76028 (the “Company”), and each party listed as a “Buyer” on the Schedule of Buyers attached thereto (collectively, the “Buyers”) are parties to the Securities Purchase Agreement, dated as of July 16, 2026 (as amended, restated, extended, replaced or otherwise modified from time to time, the “Securities Purchase Agreement”), pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase, the Notes (as defined in the Securities Purchase Agreement) issued pursuant the

…

Exhibit 10.1

Execution Version

PURCHASE AND SALE AGREEMENT

among

Rivercrest Capital Partners LP,

rivercrest capital partners ii lp, and

Cupola RoyaLty Direct, LLC,

collectively, as Sellers,

and

KIMBELL ROYALTY PARTNERS, LP,

KIMBELL ROYALTY OPERATING, LLC,

KIMBELL ROYALTY HOLDINGS, LLC,

KIMBELL INTERMEDIATE HOLDINGS, LLC,

KRP LEGACY NBR, LLC,

and

KIMBELL CREST MINERALS LLC,

collectively, as Buyer Parties

Dated as of July 16, 2026

**  **

---

** **

TABLE OF CONTENTS

Page

…

ECARX Upsizes 2025 Convertible Senior Notes to $130 Million, Secures Additional Institutional Capital Support

LONDON, Jul. 17, 2026 /PRNewswire/ -- ECARX Holdings Inc. (Nasdaq: ECX) ("ECARX" or the "Company"), a leading global supplier of intelligent automotive computing and software solutions, today announced: an amendment deed (the "Amendment Deed") to upsize the capacity for its 2025 Convertible Notes (the "2025 Notes") from US$100 million to US$130 million; a further subscription by an existing investor for an additional 2025 Note in the amount of US$15 million; and the transfer of an existing 2025 Note to a new investor.

…

** **

**REGISTRATION RIGHTS AGREEMENT **

This Registration Rights Agreement (this “Agreement”) is dated as of July 16, 2026, by and among Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of July 16, 2026, between the Company and each Purchaser (the “Purchase Agreement”).

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each of the Purchasers agree as follows:

1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Advice” has the meaning set forth in Section 6(d).

…

**SECURITIES PURCHASE AGREEMENT **

** **

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 16, 2026, by and among Jasper** THERAPEUTICS, INC.**, a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

** **

**RECITALS **

** **

**A. **The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”) under the Securities Act.

** **

…

CONSULTING AGREEMENT

[*], 2026

IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to iSpecimen Inc. (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services.

1.	Consulting Services.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

**APPROVED BY THE STOCKHOLDERS: [    ] **

1.	**GENERAL; PURPOSE. **

(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2026 EQUITY INCENTIVE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

**APPROVED BY THE STOCKHOLDERS: [     ] **

1.	**GENERAL. **

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding Awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

**CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. **

LEASE

by and between

BMR-10255 SCIENCE CENTER LP,

a Delaware limited partnership

and

BLOSSOMHILL THERAPEUTICS, INC.,

a Delaware corporation

BioMed Realty form dated 11/18/20

---

**Table of Contents **

…

**CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. **

**BLOSSOMHILL THERAPEUTICS, INC. **

**CONSULTING AGREEMENT **

**Effective Date: August 15, 2025 **

**This Consulting Agreement **(the “Agreement”) is made as of the Effective Date set forth above by and between BlossomHill Therapeutics, Inc., a Delaware corporation (“Client”) and the consultant named on the signature page hereto (“Consultant”).

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**SEVERANCE PLAN **

**AND **

**SUMMARY PLAN DESCRIPTION **

**APPROVED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

1. Introduction. The purpose of this BlossomHill Therapeutics, Inc. Severance Plan (the “Plan”) is to provide specified severance benefits to eligible employees of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA (as defined below). This Plan shall supersede any existing severance plan or individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee’s separation from the Company. This document constitutes both the written instrument under which the Plan is maintained an

…